Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study

Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis

Catherine de Martel, Damien Georges, Freddie Bray et al. · The Lancet Global Health · 2019 · 2.4K citations · Full text

Medicine, Infectious Diseases, Oncology +17

Global burden of cancers attributable to infections in 2012: a synthetic analysis

Martyn Plummer, Catherine de Martel, Jérôme Vignat et al. · The Lancet Global Health · 2016 · 1.6K citations · Full text

Medicine, Infectious Diseases, Oncology +17

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

Elmar A. Joura, Anna R. Giuliano, Ole‐Erik Iversen et al. · New England Journal of Medicine · 2015 · 1.4K citations · Full text

Medicine, Oncology, Preventive Medicine +16

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Jorma Paavonen, David Jenkins, F. Xavier Bosch et al. · The Lancet · 2007 · 1.3K citations

Veterinary Medicine, Immunology, Oncology +17

Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices

Elissa Meites, Peter G. Szilagyi, Harrell W. Chesson et al. · MMWR Morbidity and Mortality Weekly Report · 2019 · 996 citations · Full text

Medicine, Infectious Diseases, Oncology +17